HFpEF and the Kidney: Shared Risk, Distinct Phenotypes

A heterogeneous syndrome

HFpEF involves heart failure with preserved ejection fraction and objective evidence supporting elevated filling pressures or cardiac dysfunction. Kidney disease, obesity, hypertension, atrial fibrillation, and systemic inflammation contribute in varying combinations.

Recognize overlapping symptoms

Dyspnea, exercise intolerance, edema, and fatigue can arise from congestion, anemia, pulmonary disease, deconditioning, or CKD. Preserved ejection fraction alone neither diagnoses HFpEF nor excludes clinically important heart failure.

Assess the heart–kidney profile

Combine clinical examination, echocardiography, natriuretic peptides when appropriate, kidney function, and albuminuria. Obesity and CKD influence biomarker interpretation. Consider specialist evaluation when resting studies do not explain exertional symptoms.

Treat proven targets

Relieve congestion and manage blood pressure, atrial fibrillation, obesity, diabetes, and kidney disease. Use therapies supported for the relevant HFpEF phenotype and current indication, with renal function and potassium monitoring where required.

Read trials by endpoint

Discuss SGLT2 and mineralocorticoid receptor antagonist evidence by enrolled population and measured outcomes. Changes in albuminuria, biomarkers, or mechanistic pathways do not automatically establish improvement in survival or kidney failure.

Keep mechanistic claims proportional

Inflammation, fibrosis, and kidney-mediated pathways offer useful explanatory models, but HFpEF should not be declared universally a renal disease. Phenomapping and emerging biomarkers remain distinct from a validated bedside treatment algorithm.

Self-check: Why does preserved ejection fraction alone fail to diagnose HFpEF, and how can CKD or obesity complicate natriuretic-peptide interpretation?